BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25-35. [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Keating GM. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016;76:1203-1211. [PMID: 27401997 DOI: 10.1007/s40265-016-0612-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
2 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat 2019;26:685-96. [PMID: 30739368 DOI: 10.1111/jvh.13080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Degré D, Sersté T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS One 2017;12:e0170933. [PMID: 28125694 DOI: 10.1371/journal.pone.0170933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Aygen B, Demirtürk N, Yıldız O, Çelen MK, Çelik İ, Barut Ş, Ural O, Batırel A, Mıstık R, Şimşek F, Asan A, Ersöz G, Türker N, Bilgin H, Kınıklı S, Karakeçili F, Zararsız G, Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turk J Gastroenterol 2020;31:305-17. [PMID: 32412901 DOI: 10.5152/tjg.2020.19197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Sci Rep 2019;2:e92. [PMID: 30937389 DOI: 10.1002/hsr2.92] [Reference Citation Analysis]
7 Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med 2021;16:1949797. [PMID: 34308801 DOI: 10.1080/19932820.2021.1949797] [Reference Citation Analysis]
8 Gopalakrishnan S, Mensing S, Menon RM, Zha J. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies. Clin Pharmacokinet 2018;57:1407-19. [PMID: 29516428 DOI: 10.1007/s40262-018-0640-y] [Reference Citation Analysis]
9 Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. J Med Virol 2018;90:1739-44. [PMID: 29900553 DOI: 10.1002/jmv.25243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Toyoda H. Direct-acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens. Health Sci Rep 2019;2:e106. [PMID: 30937390 DOI: 10.1002/hsr2.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Zarębska-Michaluk D. Viral hepatitis C treatment shortening - what is the limit? Clin Exp Hepatol 2019;5:265-70. [PMID: 31893236 DOI: 10.5114/ceh.2019.88085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441-445. [PMID: 29628768 DOI: 10.2147/idr.s160593] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
13 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
14 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8. [PMID: 29666174 DOI: 10.1136/gutjnl-2017-315906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
16 Gschwantler M, Bamberger T, Graziadei I, Maieron A, Katalinic N, Stauber R. Burden of disease in patients with chronic hepatitis C in the Austrian REAL study. Wien Klin Wochenschr 2019;131:8-16. [PMID: 30430232 DOI: 10.1007/s00508-018-1404-2] [Reference Citation Analysis]